Trial Profile
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2023
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Carcinoma; Liver cancer
- Focus Biomarker; Therapeutic Use
- 08 Dec 2023 Status changed from suspended to completed.
- 29 Aug 2022 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 29 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.